MUMBAI, India, May 30 -- Intellectual Property India has published a patent application (202311065382 A) filed by Petrichor Biologics Foundation, Ghaziabad, Uttar Pradesh, on Sept. 28, 2023, for 'topical sprayable haemostatic composition.'
Inventor(s) include Ravi Kumar.
The application for the patent was published on May 30, under issue no. 22/2025.
According to the abstract released by the Intellectual Property India: "The present invention introduces an innovative hemostatic spray formulation, primarily based on chitosan, presented in a viscous solution, designed to effectively address a wide range of wound severities, from minor to major. This pharmaceutical composition contains key elements: Chitosan, Gelatin, Collagen, Hyaluronic Acid, Vitamin K, and potassium alum, collectively offering an efficient means to facilitate blood clotting and mitigate excessive blood loss until the patient can access a medical facility. This patent seeks to provide a practical and efficient solution for managing critical bleeding scenarios in situations where immediate medical attention is not readily available. Chitosan, a derivative of chitin through deacetylation, boasts inherent hemostatic properties that trigger platelet activation and aggregation, instigating the clotting process. Complementing this, Gelatin, a biodegradable protein derived from collagen, acts as a reinforcing agent, augmenting the clot's strength and stability. The proposed formulation harnesses these unique attributes to promote hemostasis, expedite blood clotting, prevent bacterial infections, and facilitate wound healing. Our carefully developed hemostatic spray formulation is designed for easy and swift application, ensuring usability in emergency situations. The chitosan and gelatin composition, suspended in a suitable solvent, allows efficient spraying onto the wound area. Upon contact with blood, the formulation swiftly activates, initiating clot formation within seconds. The advantages of this innovative formulation are manifold. Firstly, it significantly reduces the risk of severe blood loss, thereby improving the survival prospects for patients with injuries ranging from minor to major. Secondly, the formulation's rapid action provides immediate relief and a sense of security to the injured individual and any accompanying first responders. Furthermore, the chitosan and gelatin-based composition in viscous solution exhibits biocompatibility, ensuring safe use without adverse effects on wound healing. Importantly, this spray not only controls bleeding but also enhances the natural wound-healing process, further contributing to a person's overall recovery. In conclusion, the novel chitosan-based hemostatic spray formulation, presented in a viscous form, represents a significant advancement in emergency medical care for managing major wounds and injuries. It offers a comprehensive solution to address various aspects of wound management, from hemostasis and infection prevention to wound healing acceleration, ultimately improving patient outcomes in critical situations."
Disclaimer: Curated by HT Syndication.
